Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

Detalles Bibliográficos
Autores principales: Hughes, T P, Leber, B, Cervantes, F, Spector, N, Pasquini, R, Clementino, N C D, Schwarer, A P, Dorlhiac-Llacer, P E, Mahon, F-X, Rea, D, Guerci-Bresler, A, Kamel-Reid, S, Bendit, I, Acharya, S, Glynos, T, Dalal, D, Branford, S, Lipton, J H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668492/
https://www.ncbi.nlm.nih.gov/pubmed/28862704
http://dx.doi.org/10.1038/leu.2017.247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668492/
https://www.ncbi.nlm.nih.gov/pubmed/28862704
http://dx.doi.org/10.1038/leu.2017.247

Ejemplares similares